A Possible Guide as a Tool to Complementary Effects of New Coronavirus
Afsaneh Sadremomtaz, Javad Hashemi, Adeleh Sahebnasagh and 8 more
Archives of Anesthesia and Critical Care · 2021
doi:10.18502/aacc.v7i4.7633 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
At the end of 2019, Sars-CoV-2 was identified and has since spread in the world. Coronavirus is commonly caused by upper respiratory tract and severe acute respiratory syndrome in humans. Due to the novel nature of the virus and high mortality among high-risk people, today health care providers used several medications with different mechanisms to overcome this virus. The course of COVID-19 represents three stages that have different symptoms and used different drugs depends on each stage. Ultimately the minority of patients progress to stage III with high mortality. The aim of this study is a comprehensive review of COVID-19 adjuvant therapies. We explained the current study on the use of Glucocorticoids, Interferon, Vitamin C, Tocilizumab, Anakinra, Pentoxifylline, IVIG, Allopurinol, Ivermectin, and Selenium in sepsis, pneumonia, and ARDS and we suggested a new protocol for prescribing each medication currently used in COVID-19 Outbreak.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.